Future treatment for asthma.
Eur Respir Rev
; 25(139): 77-92, 2016 Mar.
Article
em En
| MEDLINE
| ID: mdl-26929425
ABSTRACT
The landscape of asthma has considerably changed after 40â
years of inhaled corticosteroid development and nearly 20â
years since the first monoclonal antibodies (mAbs) were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterisation of our patients. These clinical (phenotype) or new biological (endotype) tools lead to palpable personalised medicine. This review examines not only the future of mAbs and other new ways of treating asthma but also describes futuristic views based on the paradigm shifts that are ready to occur.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Antiasmáticos
/
Descoberta de Drogas
/
Medicina de Precisão
/
Terapia de Alvo Molecular
/
Pulmão
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article